Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Author: Zhejiang Wenda Pharmaceutical Technology Co., Ltd.

Posted Date: